Literature DB >> 28137218

Metabolic and Cardiovascular Actions of Nesfatin-1: Implications in Health and Disease.

Naresh Ramesh1, Kavishankar Gawli1, Venkata Kiran Pasupulleti1, Suraj Unniappan1.   

Abstract

BACKGROUND: Metabolic homeostasis is achieved by proper functioning of a complex endocrine milieu, comprising of signals arising from the brain and peripheral tissues. Our knowledge of the factors regulating such balance is rapidly evolving, as new signaling molecules are being characterized. Of central interest is nesfatin-1, owing to its multifunctional tissue specific actions regulating food intake, body weight, blood glucose and cardiac functions.
METHOD: This review discusses the tissue/system wide distribution and actions of nesfatin-1 in regulating metabolic and cardiovascular functions in healthy conditions and diseases.
RESULTS: Nesfatin-1 is an 82 amino acid peptide encoded in the secreted precursor, nucleobinin-2 (NUCB2). It was first reported as a novel anorexigen and a fat reducing orphan ligand. Research to date has established nesfatin-1 in the regulation of food intake via modulation of neuropeptides in the feeding centers of brain. Nesfatin-1 expression was also reported to have a spectrum of peripheral tissue specific actions, which includes insulin secretion (pancreas), fat and glucose modulation (adipocyte), gastric motility and gastric acid secretion (stomach), hormone secretion and transit time (intestine) and mean arterial pressure and cardiac injury (heart). Abnormal levels of nesfatin-1 in circulation and/or variations in tissue specific expression have been observed in obesity, diabetes and cardiovascular diseases.
CONCLUSION: The multifunctional biological actions of nesfatin-1 propelled this peptide as a therapeutic target, and as a potential biomarker of diseases. However, a better and comprehensive understanding of tissue specific effects of nesfatin-1 is critical prior to exploring its possible use in the detection and treatment of diseases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Nucleobindins; adipocyte; cardiovascular functions; liver; metabolism; muscle; nesfatin-1; pancreas

Mesh:

Substances:

Year:  2017        PMID: 28137218     DOI: 10.2174/1381612823666170130154407

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Combined Effects of High-Intensity Aerobic Exercise Training and Ziziphus jujuba Extract on Tissue Nesfatin-1 in Rats.

Authors:  Abbass Ghanbari-Niaki; Fahimeh Hosseini; David Robert Broom; Bahareh Tejenjari; Saleh Rahmati-Ahmadabad
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

2.  Single Nucleotide Polymorphisms of NUCB2 and their Genetic Associations with Milk Production Traits in Dairy Cows.

Authors:  Bo Han; Yuwei Yuan; Yanhua Li; Lin Liu; Dongxiao Sun
Journal:  Genes (Basel)       Date:  2019-06-13       Impact factor: 4.096

3.  Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway.

Authors:  Zhanwei Fan; Jianjiang Dong; Yindong Mu; Xian Liu
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

4.  Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.

Authors:  Seyed Ali Jazayeri-Tehrani; Seyed Mahdi Rezayat; Siavash Mansouri; Mostafa Qorbani; Seyed Moayed Alavian; Milad Daneshi-Maskooni; Mohammad-Javad Hosseinzadeh-Attar
Journal:  Nutr Metab (Lond)       Date:  2019-01-28       Impact factor: 4.169

5.  Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome.

Authors:  Angus P Yu; Felix N Ugwu; Bjorn T Tam; Paul H Lee; Vicki Ma; Simon Pang; Angel S Chow; Kenneth K Cheng; Christopher W Lai; Cesar S Wong; Parco M Siu
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

Review 6.  Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases.

Authors:  Lucia Recinella; Giustino Orlando; Claudio Ferrante; Annalisa Chiavaroli; Luigi Brunetti; Sheila Leone
Journal:  Front Physiol       Date:  2020-10-30       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.